Last Update

2016-05-18T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Cooper Collins?

Mr. Cooper C. Collins

President and Chief Executive Officer

PERNIX THERAPEUTICS HOLDINGS, INC.

Direct Phone: (832) ***-**** ext. ****       

Email: c***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

PERNIX THERAPEUTICS HOLDINGS, INC.

10 North Park Place Suite 201

Morristown, New Jersey 07960

United States

Company Description

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and p ... more

Find other employees at this company (232)

Background Information

Employment History

Chairman and Chief Executive Officer

Fortis BioPharma

Director

TherapeuticsMD, Inc.

Biotech Hedge Fund Manager

SigmaBleyzer LLC

Affiliations

Advisory Board Member
VHS

Education

B.A.

Nicholls State University

M.B.A.

Nicholls State University

Web References (180 Total References)


Cooper C. ...

www.sec.gov [cached]

Cooper C. Collins

...
Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma since June 2015. Mr. Collins has served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Pernix is a specialty pharmaceutical company focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007, and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. We believe Mr. Collins’ specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
...
Thompson, Carroll, Collins, LaPenta, Jr., Russell and Segal, is an independent director, as “independence” is defined under the applicable rules and regulations of the SEC and the listing standards of the NYSE MKT, because they do not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors.
...
LaPenta, Jr., Segal, Collins, and Russell, each an independent director of our company under the NYSE MKT rules as well as under rules adopted by the SEC
...
Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman.
...
Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman.
...
Collins, Thompson, and Carroll served as members of the Compensation Committee.
...
Collins, Thompson, or Carroll have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation S-K under the Exchange Act.


VelocityHealth Securities

www.velocityhealth.com [cached]

Cooper C. Collins, Former CEO Pernix Therapeutic Holdings, Inc.

...
Cooper C. Collins is the Former CEO of Pernix Therapeutic Holdings, Inc. a specialty pharmaceutical company focused on the pediatric sector. During his six year career with Pernix, Mr. Collins has worked in every capacity from sales representative to the executive level. Mr. Collins has been responsible for acquiring products and assets, attracting investors and increasing the overall efficiency of the organization. As a sales representative, he improved territory sales by over 300% in the first year and quickly moved into management. While serving as President, Mr. Collins has contributed to the Company's overall profit increasing over 100% from the year ended December 31, 2007 to the year ended December 31, 2008. Prior to joining Pernix, Mr. Collins was employed by the NFL franchise The New Orleans Saints in their media relations department for three years. He also developed and sold a small internet company while earning a B.A. and a M.B.A. on a football scholarship from Nicholls State University.


TherapeuticsMD - Board Members

www.therapeuticsmd.com [cached]

Cooper C Collins: Cooper C. Collins was elected as a Director of TherapeuticsMD, Inc. on February 28, 2012. Mr. Collins was appointed President, Chief Executive Officer and director of Pernix Therapeutics Holdings, Inc. ("Pernix") effective with the close of the merger between Pernix and Golf Trust of America, Inc. on March 9, 2010. Mr. Collins joined Pernix in 2002. He was appointed a director of Pernix in January 2007, Pernix's President in December 2007, and Pernix's Chief Executive Officer in June 2008, serving in those three capacities until the closing of the GTA merger. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix and as Pernix's Territory Manager from December 2003 to December 2005. Over Mr. Collins' tenure as an executive with Pernix, he has been responsible for increasing the overall growth, profitability and efficiency of the organization, overseeing product development and acquisitions, and managing the capital structure of Pernix. Prior to joining Pernix, Mr. Collins was employed for three years by the NFL franchise, The New Orleans Saints, in their media relations department. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.


Cooper C. ...

www.sec.gov [cached]

Cooper C. Collins

...
Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Pernix is a specialty pharmaceutical company focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007, and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. We believe Mr. Collins’ specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
...
Thompson, Carroll, Collins, LaPenta, Jr., Russell and Segal, is an independent director, as “independence” is defined under the applicable rules and regulations of the SEC and the listing standards of the NYSE MKT, because they do not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors.
...
LaPenta, Jr., Segal, and Collins, each an independent director of our company under the NYSE MKT rules as well as under rules adopted by the SEC pursuant to the Sarbanes-Oxley Act of 2002.
...
Collins and Thompson, with Mr. Collins serving as Chairman.
...
Collins and Thompson, with Mr. Collins serving as Chairman.
...
Collins, Thompson, and Musing served as members of the Compensation Committee.
...
Collins, Thompson, or Musing have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation S-K under the Exchange Act.


Cooper C. ...

www.sec.gov [cached]

Cooper C. Collins

...
Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Pernix is a specialty pharmaceutical company focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007, and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. We believe Mr. Collins’ specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
...
Thompson, Stanicky, Collins, LaPenta, Jr., Musing, and Segal, is an independent director, as “independence” is defined under the applicable rules and regulations of the SEC and the listing standards of the NYSE MKT, because they do not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors.
...
Mr. Collins will be joining the Audit Committee prior to the date of the 2014 Annual Meeting of Stockholders.
...
Collins, Thompson, and Musing, with Mr. Collins serving as Chairman.
...
Collins, Thompson, and Musing, with Mr. Collins serving as Chairman.
...
Collins, Thompson, Musing, and Finizio served as members of the Compensation Committee.
...
Collins, Thompson, or Musing have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation S-K under the Exchange Act.

Similar Profiles

Other People with this Name

Other people with the name Collins

David Collins
Jacki Ruiz

Thomas Collins
2013 Copper Island Behavioral Health Services

Jon Collins

Courtney Collins
Angelica Rohner Pediatric Dentistry

Jay Collins
WEX Inc.

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory